Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
A healthcare provider must evaluate your eligibility and prescribe the medication as an adjunct to diet and exercise
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
Product Overview Active compound: Retatrutide (LY3437943) 24 mg per pen Format: Single-use, pre-filled subcutaneous pen Suggested research model: Once-weekly administration (investigational context only) Mechanistic profile: Multi-agonist peptide acting on: GLP-1 receptors GIP receptors Glucagon receptors These receptor systems regulate: appetite signaling energy expenditure insulin secretion metabolic flexibility Manufacturer: Compounded by GenPep Pharmacy , operating under GMP-aligned quality and purity standards Handling & Storage Store refrigerated at 2 C 8 C Do not freeze Protect from light and heat Use only within authorized research protocols Handle according to Good Laboratory Practices (GLP) Evidence-Based Dose Levels Used in Human Trials (Educational Context Only) Retatrutide is investigational
Animal and human research suggest that increased activity of the endocannabinoid system may lead to insulin resistance, glucose intolerance, and obesity
Rotating injection sites with each doserather than using the same location repeatedlyallows tissue recovery and reduces cumulative irritation
In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes
